CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
CANTON, Mass., April 08, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company’s CEO, will present at the 15th Annual Needham Healthcare Conference in New York City. The presentation will take place at 1:40 p.m. ET on Wednesday, April 13, 2016 at the Westin Grand Central Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza™ ER
Collegium's lead product candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza using its proprietary DETERx technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
